9F81

Crystal structure of RIOK2 with a covalent compound GCL 47

これはPDB形式変換不可エントリーです。

9F81 の概要

• エントリーDOI: 10.2210/pdb9f81/pdb
• 分子名称: Serine/threonine-protein kinase RIO2, N-(4-quinazolin-4-ylphenyl)propanamide (3 entities in total)
• 機能のキーワード: kinase, covalent, inhibitor, riok2, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 77084.21

構造登録者

Wang, G.Q.,Wydra, V.,Gehringer, M.,Knapp, S.,Structural Genomics Consortium (SGC) (登録日: 2024-05-06, 公開日: 2025-01-08, 最終更新日: 2025-02-26)

主引用文献

Wang, G.,Seidler, N.J.,Rohm, S.,Pan, Y.,Liang, X.J.,Haarer, L.,Berger, B.T.,Sivashanmugam, S.A.,Wydra, V.R.,Forster, M.,Laufer, S.A.,Chaikuad, A.,Gehringer, M.,Knapp, S.
Probing the Protein Kinases' Cysteinome by Covalent Fragments.
Angew.Chem.Int.Ed.Engl., 64:e202419736-e202419736, 2025

PubMed Abstract: Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non-covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non-conserved cysteines. Previously, covalent fragment screens yielded potent and selective compounds for individual kinases such as ERK1/2 but have not been applied to the broader kinome. Furthermore, many of the accessible cysteine positions have not been addressed so far. Here, we outline a generalizable approach to sample ATP-site cysteines with fragment-like covalent inhibitors. We present the development of a kinase-focused fragment library and its systematic screening against a curated selection of 47 kinases, with 60 active site-proximal cysteines using LC/MS and differential scanning fluorimetry (DSF) assays, followed by hit validation through various complementary techniques. Our findings expand the repertoire of targetable cysteines within protein kinases, provide insight into unique binding modes identified from crystal structures and deliver isoform-specific hits with promising profiles as starting points for the development of highly potent and selective covalent inhibitors.

PubMed: 39716901
DOI: 10.1002/anie.202419736

実験手法

X-RAY DIFFRACTION (3.02 Å)